The UCL collaboration offer

We have developed a DNA-based platform technology for therapeutic cancer vaccine design and provided proof of concept in a range of mouse tumors. The pTOP technology relies on the combined delivery of:

- A carrier sequence (e.g., vesicular stomatitis virus glycoprotein) displaying adjuvant properties
- CD8 epitopes to generate CTL responses
- CD4 helper epitopes

We aim to partner with academia and industries to develop therapeutic cancer vaccines for use in Human and to identify winning “pTOP-drug” combinations with the potential to cure more patients thanks to synergistic action modes.

Preferred partnership

Collaboration with pharmaceutical companies that develop immune checkpoint inhibitors or other immunotherapy drugs.

INTERESTED TO BENEFIT FROM THESE SERVICES?
Please contact:

Fabienne FAUCHET
Technology Transfer Advisor
+32 10 47 25 49
fabienne.fauchet@uclouvain.be
www.ltto.com